Clinical trial
Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
NCT00103727 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00103727 |
|---|---|
| Title | Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia |
| Official title | A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug, Other |
| Interventions | Talnetant, placebo, risperidone |
| Enrollment | 282 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Feb 15, 2005 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: